The Effect of Losartan Versus Amlodipine-based Therapy in Ischemic Stroke (0954-338)(COMPLETED)

The Effect of Losartan Versus Amlodipine-based Antihypertensive Therapy on Atherosclerotic Inflammatory Markers and Cerebrovascular Regulation in Ischemic Stroke Patients

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00754429

Enrollment

Registered

2008-09-18

Start date

2004-06-30

Completion date

2009-07-31

Last updated

2013-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic Stroke

Brief summary

To compare the effect of losartan vs amlodipine-based antihypertensive therapy on atherosclerotic inflammatory markers and cerebrovascular regulation in Ischemic stroke patients.

Interventions

DRUGlosartan

losartan 50mg qd for 30 weeks.

DRUGamlodipine

amlodipine 5 mg q.d for 30 weeks.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patient With Tia Or Ischemic Stroke (Event Has Occurred More Thaan 4 Weeks But Less Than 24 Weeks, And Modified Rankin'S Scale, Mrs\<=3) With Mild To Moderate Hypertension * Patient Has No Other Active Medical Problem, Which Might Of Itself Or By This Treatment Significantly Affect The Patient's Blood Pressure * The Blood Level Of Hscrp\>0.2 Ng/Dl By Two Measurements Performed Respectively One-Week Apart

Exclusion criteria

* Patients With Cardiac Arrhythmia * Diabetes Mellitus * Patient With Other Active Inflammatory Diseases Such As Rheumatoid Disease, Fever And Systemic Infection Which Will Confound The Level Of Serum CRP * Patients With Known Intolerance, Contraindication Or Hypersensitivity To Losartan, Amlodipine and Hydrochlorothiazide * Patient With Myocardial Infarction Within The Recent Three Months * Anatomy Abnormality Which Results In Poor Bilateral Temporal Acoustic Windows Which Prevent TCD Procedure * Patient Who Requires Continuous Medication With Alpha Blocking Agents * Concurrent Usage Of Acei * Poor Mental Function Or Any Other Reason To Expect Difficulty In Meeting The Requirements Of The Study * Concurrent Treatment With Other Lipid-Lowering Drug * Childbearing Potential Women Not Undergoing Adequate Contraceptive Control

Design outcomes

Primary

Measure	Time frame
MCAFV and TCD for measuring cerebral autoregulatory indices at week 0, week 6, week 18 and week 30.	At week 0, week 6, week 18 and week 30.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026